A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes

You will receive either placebo (inactive medication) or identical looking dapagliflozin 10 mg (active medication). In some circumstances, your study doctor may lower your dose to 5 mg dapagliflozin/placebo, either temporarily or for the remainder of the study. You have an equal chance of receiving placebo or dapagliflozin. Which treatment you receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither you nor the study doctor will know which treatment you have received. The study medications should be taken once a day, at approximately the same time every day, and be swallowed whole. Your participation in this study involves about 9-17 visits over approximately 1.5-4 years depending on when you enter the study. This may be shortened or extended (and visit added or removed) as the study will be closed when enough data has been collected to evaluate the results. At these visits you will for example be asked to provide blood and urine samples, undergo physical examinations and complete health questionnaires.